MAP2K7 and neoplasm: Jiang et al. [251] recently found that collateral inhibition of MEK (using cobimetinib) and autophagy (using mefloquine), but not either treatment alone, activates the STING/type I interferon pathway in tumor cells, which in turn activates paracrine tumor-associated macrophages toward an immunogenic M1-like phenotype.